Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025)

Iridex (IRIX) recorded quarterly Asset Writedowns and Impairment of $800000.0 in Q3 2025, up 892.08% quarter-over-quarter from -$101000.0 in Q1 2022.

Iridex (IRIX) Asset Writedowns and Impairment (2011 - 2025) Analysis & Trends

Iridex's Asset Writedowns and Impairment history runs 11 years deep, the most recent figure standing at $800000.0 for Q3 2025.

In Q3 2025, Asset Writedowns and Impairment changed N/A year-over-year to $800000.0; the TTM figure through Jan 2026 stood at $800000.0 (up 1350.0% YoY), while the FY2026 annual figure was $823000.0, changed N/A from the prior year.
Asset Writedowns and Impairment was $800000.0 for Q3 2025 at Iridex, up from -$101000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $800000.0 in Q3 2025 to a low of -$101000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn
10	Iridex	19.91 Mn	15.31 Mn	4.74 Mn

Download Data